Nasdaq

Diffusion Pharmaceuticals Completes Phase 1b Study of TSC in Hospitalized COVID-19 Patients

CHARLOTTESVILLE, Va., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel therapies ...
Nasdaq

Diffusion Pharmaceuticals Appoints Dr. Chris Galloway as Chief Medical Officer

CHARLOTTESVILLE, Va., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or “the Company”), today announced the ...
FiercePharma

New Patents Issued to Diffusion Pharmaceuticals

Diffusion Pharmaceuticals LLCMedia:David G. Kalergis, MBA/JDCEO434-220-0718orGBM Study Information:Kim Whitten, Pharm.D,Vice President, Drug Development434-220-0718 Diffusion Pharmaceuticals LLC, a ...
Pharmabiz

Diffusion Pharma gets positive results in phase I/II trial of Trans Sodium Crocetinate in peripheral artery disease

Diffusion Pharmaceuticals LLC announced positive results of its phase I/II proof-of-concept study of Trans Sodium Crocetinate (TSC) in patients suffering from walking impairment due to Peripheral ...